Vaginal microbicides: A novel approach to preventing sexual transmission of HIV

Doncel, Gustavo F.; Mauck, Christine

doi:10.1007/s11904-004-0004-0

Cited by 20 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaginal microbicides were identified as a promising means for women in developing countries to protect themselves from sexual transmission of HIV (Doncel and Mauck 2004). Because pregnancy is a marker of unprotected sexual activity, understanding the effects of a medication aimed at mitigating the risks of such exposure is particularly important for this group.…”

Section: Access To the Prospect Of Direct Benefitmentioning

confidence: 99%

The second wave: Toward responsible inclusion of pregnant women in research

Lyerly¹,

Little²,

Faden³

2008

International Journal of Feminist Approaches to Bioethics

View full text Add to dashboard Cite

Though much progress has been made on inclusion of non-pregnant women in research, thoughtful discussion about including pregnant women has lagged behind. We outline resulting knowledge gaps and their costs and then highlight four reasons why ethically we are obliged to confront the challenges of including pregnant women in clinical research. These are: the need for effective treatment for women during pregnancy, fetal safety, harm from the reticence to prescribe potentially beneficial medication, and the broader issues of justice and access to benefits of research participation. Going forward requires shifting the burden of justification from inclusion to exclusion and developing an adequate ethical framework that specifies suitable justifications for excluding pregnant women from research.

show abstract

Section: Access To the Prospect Of Direct Benefitmentioning

confidence: 99%

The second wave: Toward responsible inclusion of pregnant women in research

Lyerly¹,

Little²,

Faden³

2008

International Journal of Feminist Approaches to Bioethics

View full text Add to dashboard Cite

show abstract

“…A vaccine, which would provide an ideal strategy, is not yet available. In the light of these limitations, novel preventatives, such as a topical microbicide or an oral preexposure prophylactic (PrEP), are an urgent goal (13,37,51).…”

mentioning

confidence: 99%

Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors

McFadden

Fletcher

Rossi

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The first stage of human immunodeficiency virus type 1 (HIV-1) infection involves the fusion of viral and host cellular membranes mediated by viral envelope glycoprotein gp120. Inhibitors that specifically target gp120 are gaining increased attention as therapeutics or preventatives to prevent the spread of HIV-1. One promising new group of inhibitors is the peptide triazoles, which bind to gp120 and simultaneously block its interaction with both CD4 and the coreceptor. In this study, we assessed the most potent peptide triazole, HNG-156, for inhibitory breadth, cytotoxicity, and efficacy, both alone and in combination with other antiviral compounds, against HIV-1. HNG-156 inhibited a panel of 16 subtype B and C isolates of HIV-1 in a single-round infection assay. Inhibition of cell infection by replication-competent clinical isolates of HIV-1 was also observed with HNG-156. We found that HNG-156 had a greater than predicted effect when combined with several other entry inhibitors or the reverse transcriptase inhibitor tenofovir. Overall, we find that HNG-156 is noncytotoxic, has a broad inhibition profile, and provides a positive combination with several inhibitors of the HIV-1 life cycle. These results support the pursuit of efficacy and toxicity analyses in more advanced cell and animal models to develop peptide triazole family inhibitors of HIV-1 into antagonists of HIV-1 infection.

show abstract

“…Topical microbicides are a promising strategy for reducing the sexual transmission of human immunodeficiency virus type 1 (HIV-1) and other genital tract infections (16,42). In order to be effective, these products must support the natural barrier function of the genital tract mucosa.…”

mentioning

confidence: 99%